GALT Research | Milton Maxwell

GALT

Galectin Therapeutics Inc.

6.20

-0.31-4.76%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

399.77M

P/E (TTM)

Basic EPS (TTM)

-0.59

Dividend Yield

Recent Filings

8-K

Annual meeting results

12/8/25Dec 8, 2025

Galectin Therapeutics stockholders at the December 3, 2025 annual meeting re-elected all 11 director nominees with strong support, averaging over 25M votes for amid 19.5M broker non-votes. They approved executive pay on an advisory basis and ratified Cherry Bekaert as auditors for 2025 with 45.5M votes for. Board set exec comp votes every three years.

8-K

NAVIGATE biomarker boost

12/3/25Dec 3, 2025

Galectin Therapeutics presented detailed NAVIGATE trial analyses post-annual meeting on December 3, 2025, bolstering belapectin's topline results. In completers, 2 mg/kg belapectin cut new varices versus placebo, backed by FibroScan stability, >50% PRO-C3 drop, ELF benefits, and YKL-40 reductions signaling antifibrotic action. Data reinforced safety; FDA feedback and partnerships await. Momentum builds.

8-K

NAVIGATE: 40% varices reduction

9/8/25Sep 8, 2025

Galectin Therapeutics posted an updated corporate presentation on September 8, 2025, highlighting NAVIGATE trial's 18-month results: belapectin cut new varices incidence by ≥40% versus placebo in ITT and per-protocol MASH cirrhosis patients. Belapectin 2 mg/kg showed consistent efficacy; safety matched placebo. FDA feedback planned by year-end.

10-Q

Q2 FY2025 results

8/14/25Aug 14, 2025

Galectin Therapeutics trimmed Q2 operating loss to $4.6M from $11.3M y/y, driven by R&D spend dropping 67% to $3.3M as the NAVIGATE trial wrapped up. Cash burn eased to $14.3M YTD from $20.4M y/y, ending June 30, 2025 with $13.8M cash; related-party lines funded $11M net inflows. Debt stands heavy at ~$120M related-party notes/lines maturing September 2026, offset by a fresh $10M line signed July 8. Net loss widened to $7.5M from operating due to $1.1M derivative fair-value hit and $1.8M interest. Warrants keep diluting. Clinical delays loom large.

8-K

Q2 loss narrows post-trial

8/14/25Aug 14, 2025

Galectin Therapeutics reported Q2 2025 results, posting a $7.6M net loss on $3.3M R&D spend—down sharply from $9.8M last year after NAVIGATE trial wrapped. Cash stood at $13.8M as of June 30, bolstered by a $10M chairman line of credit funding ops through mid-2026. Belapectin sustained liver stiffness reductions and fewer varices in extended trial data. FDA talks loom.

About

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

CEO

Mr. Joel Lewis CPA

IPO

9/4/2002

Website

https://galectintherapeutics.com

Employees

Sector

Healthcare

Industry

Biotechnology